Practical considerations in the use of regorafenib in metastatic colorectal cancer.

ABSTRACT: Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC) has improved considerably, leading to increased overall survival and more patients eligible for third- or later-line therapy. Currently, two oral therapies are recommended in the third-line treatment of mCRC, regorafenib and trifluridine/tipiracil. Selecting the most appropriate treatment in the third-line setting poses different challenges compared with treatment selection at earlier stages. Therefore, it is important for physicians to understand and differentiate between available treatment options and to communicate the benefits and challenges of these to patients. In this narrative review, practical information on regorafenib is provided to aid physicians in their decision-making and patient communi

SUBMITTER: Loupakis F 

PROVIDER: S-EPMC7607787 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature